No known hypersensitivity to Escherichia (E.) coli-derived products
Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization
Suspected or known closure of salivary gland ducts on either side
Patients with known hypersensitivity to anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate
Participants with known hypersensitivity to modafinil, armodafinil, or any of its components
Patients who are known to be hypersensitive to aprepitant, granisetron or any of the components of the patch or to dexamethasone
Subjects with a known allergy to lidocaine
Known or suspected allergy or hypersensitivity to any component of TH-302, sorafenib, or any of the sorafenib excipients
Known hypersensitivity to any component of testosterone
Patients with non-secretory MM or known amyloidosis are not eligible
History of hypersensitivity to other psychostimulants
Known hypersensitivity to any of the components of the study drugs
Patients with a known allergy or hypersensitivity to CHG are ineligible
Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
TREATMENT: Patients with known hypersensitivity reaction to dacarbazine are ineligible to receive temozolomide
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
Patients must not have known hypersensitivity reactions, such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Steven-Johnson syndrome, and toxic epidermal necrolysis to interferon alpha or any other products component
A history of glucose-6-phosphate dehydrogenase (G6PD) deficiency
Patients with a known or suspected hypersensitivity to GM-CSF, hetastarch, corn, dimethyl sulfoxide (DMSO), fetal bovine serum, or trypsin (porcine origin)
Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)
Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment
No known history of severe hypersensitivity reactions to any of the components of efatutazone or paclitaxel formulations
Patients with known hypersensitivity to any TZD oral agents are not eligible
Patient has hypersensitivity to bortezomib, boron, or mannitol
Patients with known hypersensitivity to temozolomide or dacarbazine are not eligible
Patients with known hypersensitivity to any TZD oral agents are not eligible
Patient must not have known sensitivity to terameprocol or any formulation excipients
Patients with known pre-existing diabetes mellitus will be excluded from study
Patients with known macular degeneration, uncontrolled glaucoma, or cataracts are not eligible
Patients with known disorders associated with hemolysis
Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor EL
Any known UGT1A polymorphism, heterozygous or homozygous
Known allergy to boron or excipients in the formulation
Patients with known hypersensitivity to NT-I7 or any component used in the vehicle/formulation are ineligible
Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency will be excluded
Patient does not have known glucose?6?phosphate dehydrogenase (G6PD) deficiency (G6PD testing optional)
Patients with self-reported or known diagnosis of G6PD deficiency
History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents
Undetectable haptoglobin or evidence of glucose-6-phophate dehydrogenase (G6PD) deficiency, pyruvate kinase deficiency, hemoglobinopathy, hereditary spherocytosis, thalassemia or other disorder associated with hemolysis
Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded; pre-registration testing for G6PD is at the investigators discretion and is not required for study enrollment
No known hypersensitivity or contraindication to the components of study treatment (M6620 [VX-970], gemcitabine)
Patients who have severe hypersensitivity to irinotecan hydrochloride (HCl)
Patients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorin
Known homozygous DPD (dihydro pyrimidine dehydrogenase) deficiency
Patients must not have any known contraindication to CSFs prior to registration, including prior hypersensitivity to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, or tbo-filgrastim
Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation
Hypersensitivity to MK-3475 (pembrolizumab) or any of its excipients;
Patients with history of hypersensitivity to conductive hydrogel are not eligible
Patients with known pre-existing diabetes mellitus
Patients with hypersensitivity to albumin are not eligible
No known allergy to 5-fluorouracil, oxaliplatin, or leucovorin
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec (T-VEC) or any of its components
Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI4736) and/or tremelimumab formulation
History of hypersensitivity active or inactive excipients of AZD9291 (osimertinib) or drugs with a similar chemical structure or class to AZD9291 (osimertinib)
Patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components, capecitabine, fluorouracil (5-FU) and / or oxaliplatin are ineligible
Patients with a known dihydropyrimidine dehydrogenase (DPD) deficiency are ineligible
Patients known to have hypersensitivity to dacarbazine (DTIC) are not eligible